Dr Judy :

https://wearethene.ws/notable/220526

Anon finds references for Suamin and Autism

1. Suramin and Autism Suramin is a 100-year-old drug developed to treat African sleeping sickness and river blindness. Though it has been investigated for other diseases, including cancer, it is not approved for any therapeutic use in the United States. However, a small, randomized clinical trial conducted by Robert Naviaux, MD, PhD , professor of medicine, pediatrics and pathology, and colleagues at University of California San Diego School of Medicine have found that a single intravenous dose of suramin produced dramatic, but transient, improvement of core symptoms of autism spectrum disorder (ASD). Currently, there are no drugs approved for treating the core symptoms of ASD.

More broadly, the trial findings support the “cell danger response theory,” which posits that autism and other chronic conditions are fundamentally driven by metabolic dysfunction—and thus treatable. Naviaux and his co-authors propose larger, longer clinical trials to assess suramin (or similar drugs) as an ASD treatment. …

https://health.ucsd.edu/news/topics/suramin-autism/pages/default.aspx

https://archive.is/9Y6ma

2. '''Autism and Suramin in the Time of COVID-19' May 13, 2020 — Autism spectrum disorder (ASD) is a complicated condition with multiple causal factors. At the most basic level, we believe ASD is the result of a multisystem cellular response to environmental and genetic stresses. Called the cell danger response, it results in over-release of ATP, the fundamental carrier of energy. Too much ATP signaling disrupts normal functioning in many types of cells, including how neurons communicate and work together.

Suramin is a century-old drug used to treat African sleeping sickness or trypanosomiasis. It works by inhibiting ATP signaling. In animal studies and in a small Phase I/II clinical trial completed in 2017, we reported that suramin produced dramatic reductions in classic ASD symptoms, such as social abnormalities and learning disabilities. These improvements were temporary, and disappeared in about 8 weeks after the single dose of suramin wore off. We are now in development of a second, larger clinical trial. Progress toward this trial has been slow but steady, no surprise given the complexity of ASD and the need to advance this novel approach carefully, fully supported by empirical evidence and best scientific practices.

Like labs around the world, we have not been immune from the effects of the SARS-CoV-2 pandemic. It has caused some delays and complications. Nonetheless, we expect to have all approvals in place to launch the second trial in spring of 2021.''

https://health.ucsd.edu/news/topics/Suramin-Autism/Pages/COVID-19-Response.aspx https://archive.is/wip/6i9KE

3. Updates at Dr. Naviaux website https://naviauxlab.ucsd.edu/